Introduction
Initially identi®ed as gene products whose function was the negative control of cell dierentiation, Id proteins were soon recognized as molecules coordinating the inhibition of dierentiation with a constellation of cellular functions including proliferation and cell cycle progression, migration and invasiveness, cell fate determination and angiogenesis Norton, 2000; . Id proteins impinge on these cellular properties through a pleiotropic ability to aect multiple molecular pathways. When deregulated, the cellular capabilities networked by Id proteins collectively dictate malignant transformation. Two fundamental functions of Id proteins greatly contribute to their role as potential cancer genes. First, the fact that at least one member of the Id family, Id2, is a functional target of the retinoblastoma protein (Rb) suggests that Id proteins are crucial components of the cell cycle machinery whose deregulated expression might confer a proliferative advantage to tumor cells (Lasorella et al., 2000) . Thus, one of the reasons why tumor cells might boost expression of Id2 is the demonstrated ability of high levels of Id2 to functionally eliminate the Rb tumor suppressor pathway, a process that is widely viewed as a hallmark of cancer (Iavarone et al., 1994; Lasorella et al., 1996) . Second, the identi®cation of Id1 and Id3 as cooperating genes for tumor-mediated angiogenesis raises the intriguing possibility that recruitment of blood vessels during human tumorigenesis might require Id activity (Lyden et al., 1999) . In this review, we will present the newest ®ndings of this rapidly expanding ®eld, which is witnessing a bewildering involvement of Id in tumorigenesis. We will also entertain a discussion on the implications of the role of Id proteins in human cancer and speculate on Id proteins as new therapeutic targets for cancer therapy.
Id and cell proliferation
There is overwhelming evidence favoring the view that Id proteins are essential proliferative factors for a large variety of cell types (Barone et al., 1994; Hara et al., 1994; Lyden et al., 1999; Mori et al., 2000; Wang et al., 2001; Lasorella et al., 2002) . Expression of Id proteins is rapidly induced by serum and high levels persist throughout S phase (Christy et al., 1991; Hara et al., 1994 Hara et al., , 1997 Lasorella et al., 2000; Yates et al., 1999) . A number of studies have proposed that G1 progression requires the cooperative action of Id proteins on their natural targets. Among these targets, signaling through Id proteins in vivo converges upon bHLH, Ets, Pax and perhaps other transcription factors that form complexes with Id (Benezra et al., 1990; Norton, 2000; Roberts et al., 2001; Yates et al., 1999) . Binding to Id proteins prevents DNA binding and results in loss of transcriptional activity of the engaged factor. It is still unknown, however, whether inhibition of each transcription factor is essential for the positive role of Id proteins on cell proliferation. In mammalian cells, a crucial checkpoint control for proliferation is provided by the pocket proteins of the Rb family (Rb, p107, p130) (Sherr, 1996; Weinberg, 1995) . A member of the Id family, Id2, binds to each of the three pocket proteins in a cell-cycle regulated fashion and, when in large excess, inhibits their antiproliferative function (Iavarone et al., 1994; Lasorella et al., 1996 Lasorella et al., , 2000 . What is the physiologic role of the Rb-Id2 interaction for regular cell cycle progression? Two main arguments favor a model in which Id2 operates as a downstream target of the Rb family of proteins: the rescue of embryonic lethality of Rb-null mice by ablation of Id2 and the large excess of active, hypophosphorylated pocket proteins over Id2 in normal cells (Lasorella et al., 2000) . But if Rb must keep control of Id2 to implement its anti-proliferative function, which are the pathways that signal following the Rb-mediated inactivation of Id2? It is likely that one or more targets of Id2 (bHLH, Ets, Pax, etc.) are essential eectors of the Rb-mediated cell cycle arrest and their activity requires restraint of Id2 function by Rb. In addition to Id2, transcription factors of the E2F family are also essential for Rb function (Dyson, 1998) . However, the relationship between cellular Rb-E2F and Rb-Id2 complexes is poorly understood. It is possible that the same molecule of Rb will bind Id2 and E2F. Alternatively, Id2 and E2F will compete for binding to Rb. In the ®rst scenario, in which Id2 and E2F are simultaneously targeted by Rb, Id2 and E2F are involved in independent functions orchestrated in combination to allow cell cycle progression. In this model, the cellular excess of pocket proteins is the main safeguard mechanism of negative control on cell cycle progression. The abundant Rb-Id2 and p107-Id2 complexes that are found in S phase may extinguish the action of Id2 on its natural targets, after the relatively unopposed Id2 activity that characterizes G1 progression. The negative role of pocket proteins on Id2 could be essential for progression through the S phase and cell survival. In the second model, in which Id2 and E2F compete for Rb binding, at least some functions of Id2 might result from the release of the restraining activity of the pocket proteins on E2F transcription. The two models are not mutually exclusive. A stoichiometric excess of Id2 over active Rb may prevent anti-proliferative signaling from Id2 targets and, at the same time, relieve E2F transcription from the repressive in¯uence of Rb. The recent demonstration that Id1 inhibits Ets-mediated transcription of p16
Ink4a , a tumor suppressor gene operating in the same pathway as Rb, suggests that abnormal production of Id will inactivate the Rb pathway directly (Id2 and maybe Id4) and indirectly, through inhibition of p16
Ink4a , a feature that is probably shared by the four Id proteins (Ohtani et al., 2001) . Another mechanism proposed to regulate the role of Id proteins in cell cycle progression and proliferation is phosphorylation (Deed et al., 1997; Hara et al., 1997; Nagata et al., 1995; Nagata and Todokoro, 1994) . Although phosphorylation sites have been identi®ed in vivo and changes in Id activities, such as their binding anity for bHLH transcription factors, have been described following speci®c phosphorylation events, the biologic consequences of Id phosphorylation remain elusive. Interestingly, Id2 and Id3 are phosphorylated by cyclin E-cdk2 and cyclin A-cdk2 in S phase (Deed et al., 1997; Hara et al., 1997) . As for E2F1, cdk2-mediated phosphorylation of Id2 and Id3 might be a mechanism to extinguish their activity and allow progression to the next phase of the cell cycle (Krek et al., 1994) .
Because overexpression of Id proteins in tissue culture cells results in extended proliferation, it seems likely that a similar eect will be generated in tumor cells that express abnormal amounts of Id proteins. Id ablation experiments were recently performed in neuroblastoma and in pancreatic and mammary carcinoma using oligonucleotide antisense (Klee et al., 1998; Lin et al., 2000; Lasorella et al., 2002) . Partial elimination of Id2 in neuroblastoma and pancreatic carcinoma and Id1 in mammary carcinoma decreased proliferation. In some cases reduced proliferation was associated with dramatic inhibition of the malignant behavior of the tumor cells. These experiments lend signi®cant credibility to the hypothesis that tumor cells depend, at least in part, on Id expression for unrestricted proliferation and perhaps for other phenotypic features of malignant transformation.
Many of the new capabilities acquired by malignant cells recapitulate normal characteristics of embryonal cells (Evan and Vousden, 2001; Hanahan and Weinberg, 2000) . This is especially true for tumors arising in children. These tumors (such as neuroblastoma, medulloblastoma, rhabdomyosarcoma, etc.) are thought to derive from alterations of the normal processes that control proliferation and dierentiation during development (Walterhouse and Yoon, 1997). It is therefore not surprising that the analysis of mechanisms underlying the role of Id proteins in normal development has yielded signi®cant insight into tumorigenesis. Id1, Id3 double null mice display defective proliferation and premature dierentiation in the developing brain suggesting that the combined action of Id1 and Id3 is essential for proliferation of neural progenitors in vivo (Lyden et al., 1999) . Consistent with the small body phenotype associated with elimination of Id2 in the mouse, proliferation of various cell types requires intact Id2 (Mori et al., 2000; Wang et al., 2001; Yokota et al., 1999; Lasorella et al., 2002) . So far, we know that mammary epithelial cells, oligodendrocyte precursor cells and embryonic ®broblasts rely on Id2 for proliferation but it is possible that Id2 is critical for proliferation of many, if not all, cell types.
Taken together, the results discussed above imply that Id proteins contribute signaling pathways that are essential for progression of the cell division cycle. In normal cells, the cell-cycle speci®c interactions between pocket proteins and Id2 ensure that, like for E2F transcriptional activity, the Rb family properly controls Id2-dependent events. But when, as a consequence of the oncogenic transformation, Id2 accumulates in excess over the active forms of Rb, Id2 will escape the negative control of its physiologic regulator. Ultimately, it will be the uncontrolled ®ring of events downstream of Id2 that likely overrides the Rb tumor suppressor checkpoint in human cancer (Figure 1 ). The identi®cation of these events should oer important insights on the physiologic mechanisms promoting G1 progression. It should also explain why Rb must repress Id2 to ful®l its antiproliferative and tumor suppressor function.
Ets transcription factors might be some of the targets of deregulated expression of Id proteins in human tumors. Recent studies showed that Id proteins bind Ets1 and Ets2 preventing DNA binding and Etsmediated transcriptional activation (Yates et al., 1999) . A relevant transcriptional target of Ets is the tumor suppressor gene p16 Ink4a and Id proteins inhibit expression of p16
Ink4a through the inactivation of Ets (Ohtani et al., 2001) . This mechanism may be important during replicative senescence of primary ®broblasts, when elevation of p16
Ink4a is accompanied by loss of Id proteins (Alcorta et al., 1996; Hara et al., 1994 Hara et al., , 1996 . By preventing expression of p16 Ink4a , deregulated Id proteins might use an additional tool to inactivate the Rb pathway in cancer. A role for Id in the functional inactivation of p16
Ink4a received support by a recent study conducted in early melanoma where reduced expression of p16
Ink4a correlated with marked elevation of Id1 (Polsky et al., 2001) .
Id as potential oncogenes
Tumor cells use various strategies to disrupt pathways leading to terminal dierentiation, a process known as anaplasia. This is often associated with the ability to constitutively activate growth signaling (Evan and Vousden, 2001; Hanahan and Weinberg, 2000) . One strategy to eciently accomplish both aims would be to deregulate Id protein expression. The consequences of ectopic expression of Id proteins have been analysed in a number of cell types (for review see Norton, 2000; . First, it has been shown that overexpression of Id proteins, albeit at variable levels and with notable dierences in the various cell types, enhances cell proliferation and renders cells insensitive to growth factor depletion (Iavarone et al., 1994; Norton and Atherton, 1998) . Second, at least two members of the Id family, Id2 and Id4, have been found to confer features of transformation, such as the ability to grow in soft agar, when overexpressed in NIH 3T3 ®broblasts and mammary carcinoma cells, respectively (Lasorella et al., 2002; Beger et al., 2001) . Interestingly, recent work identi®ed Id4 as a Brca1-regulating gene, whose expression decreases Brca1 and enhances tumorigenicity of breast cancer cells (Beger et al., 2001) . However, the mechanism through which Id4 interferes with the upstream Brca1 regulatory pathway is still unknown. There are also indications that Id genes might share some of the properties of immortalizing' oncogenes (Alani et al., 1999; Nickolo et al., 2000; Norton and Atherton, 1998) . When expressed in primary rodent ®broblasts, Id proteins In neuroblastoma, N-myc ampli®cation and overexpression induces accumulation of Id2 to levels exceeding active Rb. Id2 would be free to inhibit transcription of the natural targets that control cell proliferation. E, E-box generate`immortal' foci and display a cooperative eect when co-expressed with ras (Norton and Atherton, 1998) . It was also reported that constitutive expression of Id1 could immortalize primary keratinocytes (Alani et al., 1999) . However, a more recent study in which Id1 expression in keratinocytes was driven by retroviral vectors in the absence of drug selection showed that expression of Id1 could extend the life span but was not sucient for immortalization (Nickolo et al., 2000) . Probably built as an important limiting factor to the growth promoting capacity, the pro-apoptotic ability of Id proteins might provide a counterforce to prevent full immortalization (Florio et al., 1998; Kee et al., 2001; Norton and Atherton, 1998) . Thus, it was not surprising that inhibition of apoptosis by members of the Bcl-2/Bcl-x antiapoptotic family greatly enhanced Id-mediated immortalization. By sharing the dual ability to stimulate cell proliferation and cell death, Id proteins join the group of bona ®de growthpromoting proteins. For example, Myc and E2F1 are powerful activators of apoptosis and, at least in the case of Myc, the oncogenic action is strongly potentiated by survival genes of the Bcl-2/Bcl-x family (Dyson, 1998; Grandori et al., 2000) .
Probably the strongest evidences developed so far to justify the inclusion of Id in the group of nuclear oncogenes are three independent studies where transgenic mouse lines were engineered to express Id1 and Id2 in the lymphoid system and Id1 in the small intestine (Kim et al., 1999; Morrow et al., 1999; Wice and Gordon, 1998) . Targeted expression of Id1 and Id2 in T cells generated aggressive thymic lymphoma which rapidly killed the mouse (Kim et al., 1999; Morrow et al., 1999) . As a further indication of the broad phenotypic spectrum that may arise from Id activation, expression of Id1 in intestinal epithelial cells generated seemingly benign intestinal adenomas (Wice and Gordon, 1998).
Because deregulation of Id proteins is spread among multiple types of human cancer (Table 1) , there is compelling pressure to generate murine models where transgenic Id expression in dierent cell lineages could recapitulate speci®c biologic features of human malignancies. Such models would provide invaluable systems for the functional screening of candidate Id targets as well as pre-clinical testing of new anti-Id drugs.
Id in development and cancer of the nervous system
A widely accepted assumption postulates that Id proteins are abundant in proliferating, undierentiated cells but low or undetectable levels of Id are present in post-mitotic, dierentiated and senescent cells (Norton, 2000) . Probably, this can still be considered the rule. However,`exceptions' have now been described for a number of cell types in which high levels of Id proteins were found in dierentiated cells that have exited the cell cycle (Chen et al., 1999; Cooper et al., 1997; Ishiguro et al., 1996; Jen et al., 1997; Neuman et al., 1993) . This behavior typically concerns Id2 and Id4 that are expressed by a variety of dierentiating cell types from the neuroectodermal lineage. Whether or not Id have tissue-speci®c functions in these cell types is unknown. A report indicated that Id2, when overexpressed, determines cell fate speci®cation in the ectoderm by driving cells along the neural crest phenotype while suppressing the epidermal lineage (Martinsen and Bronner-Fraser, 1998) . On the other hand, the abnormal overgrowth of neural crest clusters in this system is consistent with a proliferative advantage conferred to these cells by overexpression of Id2.
A possible explanation for the expression of Id in dierentiating cells could be to ensure the persistence of a temporarily inactive proliferative machinery ready to resume activity under special circumstances (Lasorella et al., 2000) . In normal conditions, Id proteins in post-mitotic cells would be kept under strict negative control by upstream regulators. This model is illustrated by the control of Rb upon Id2, a critical mechanism to prevent inappropriate Id2 signaling in dierentiating neurons (Lasorella et al., 2000) . In the absence of Rb, neurons undergo ectopic proliferation and apoptosis (Lee et al., 1994; Slack et al., 1998) . Interestingly, these defects are rescued by ablation of Id2 in vivo and are recapitulated in vitro by overexpression of Id2 in normal cortical progenitors (Lasorella et al., 2000; Toma et al., 2000) . By inhibiting Id2 function, Rb has been proposed to collaborate with It is possible that other negative regulators of Id function will be discovered in the near future. A recent study proposed that dierentiation of oligodendrocyte precursor cells requires nuclear exclusion of Id2 (Wang et al., 2001 ). It will be interesting to test whether regulation of subcellular location will be of general importance in other cell lineages and whether it also pertains to other members of the Id family. Nuclear exclusion of Id proteins may be accomplished through a dominant mechanism, for example by cytoplasmic proteins sequestering Id. Identi®cation of these factors should oer new tools for the ongoing eorts aimed at extinguishing Id function in tumor cells carrying deregulated expression of Id.
Id proteins in tumor angiogenesis and tissue invasion
In the whole organism, two novel capabilities must be imposed upon mammalian cells to fully manifest the transformed phenotype: the ability to produce matrixdegrading proteases and the ability to promote growth of new blood vessels (Hanahan and Weinberg, 2000) . The ®rst is used by tumor cells to facilitate invasiveness into neighboring tissues, the second is essential to supply oxygen and nutrients for the expanding tumor mass. It is remarkable that both of these capabilities appear to require the participation of Id proteins.
In studies conducted in mammary epithelial cells, forced expression of Id1 not only prevented dierentiation and increased proliferation but also conferred the ability to migrate and invade the basement membrane to otherwise non-tumorigenic cells (Desprez et al., 1995 (Desprez et al., , 1998 . This phenotype appears to be related to the production of a novel metalloproteinase of 120 kD by Id1-expressing cells. Thus, it was not unexpected to ®nd that the most aggressive breast cancer cell lines and primary tumors showed deregulated expression of Id1 (Lin et al., 2000) .
Probably one of the most exciting functions recently attributed to Id proteins is their role in the angiogenesis of malignant tumors. This property was ®rst described in a study reporting the generation of Id17/7, Id3+/7 double mutant mice (Lyden et al., 1999) . Remarkably, these mice failed to support the growth of tumors and metastasis from a variety of xenografts and cancer-predisposing mutations due to poor vascularization with consequent necrosis of the tumor cells. Lack of MMP2 metalloproteinase activation and downregulation of integrins in tumor blood vessels of Id mutant mice may provide an explanation for the angiogenic defect. However, recent data demonstrated that transplantation of wild-type bone marrow-derived cells expressing VEGF receptors functionally restore tumor angiogenesis in Id mutant mice (Lyden et al., 2001) . Accordingly, disruption of Id1 and Id3 appears to result in the failure to mobilize bone marrow precursors that are essential for the neovascular postnatal process. Thus, VEGF-induced activation of Id1 and Id3 may be a critical molecular event required to promote mobilization of bone marrow precursors. In conclusion, there is now convincing evidence for a cooperative action of Id1 and Id3 in neoangiogenesis, a vital process for continuous growth of tumor cells. It is likely that signaling pathways initiated by tumor cells and involved in the recruitment of neighboring endothelium and in the mobilization of bone marrow precursors trigger multiple Id gene responses in the target cells. The detection of abnormally high expression of Id1 and Id3 in endothelial cells in®ltrating human neuroblastoma, medulloblastoma and glioblastoma multiforme (Lyden et al., 1999) raises the possibility that spontaneous human tumors require signaling converging on Id proteins for neovascularization.
Deregulation of Id in primary tumors
Numerous recent in situ hybridization and immunohistochemical studies reported on the dysregulated expression of Id proteins in a large variety of human tumors (Table 1) . Additionally, Id protein expression has been proposed as potential prognostic factor for breast and cervical cancer as well as neuroblastoma (Lin et al., 2000; Schindl et al., 2001; Lasorella et al., 2002) . Elevation of Id1 correlates with a more aggressive subset of breast cancer and is an independent marker for tumor progression in cervical cancer. Id2 overexpression, on the other hand, is strongly predictive of poor outcome in children with neuroblastoma, irrespective of other clinical and biological variables. Thus, the immunohistochemical analysis of Id protein expression has considerable potential to enter in the practical use for the routine assessment of cancer patients. However, alterations of Id genes have never been described in human cancer. This simple fact prevents us from attaching the classical label of oncogenes' to Id. It is possible that the lack of genetic lesions of Id re¯ects the participation in oncogenic networks initiated by genetic alterations of upstream regulators. An example of this interplay is the constitutive activation of the N-Myc-Id2 pathway in neuroblastoma, a highly malignant embryonal tumor derived from the neural crest (Lasorella et al., 2000; Maris and Matthay, 1999) . This pathway operates through the primary ampli®cation and/or overexpression of the N-myc oncogene. Elevation of Id2 in this tumor is a secondary event to the accumulation of NMyc transcription factors that directly bind to the Id2 promoter and activate its abnormal transcription. The ultimate outcome is the accumulation of the Id2 protein at levels that are sucient to inactivate the Rb pathway. Thus, neuroblastoma represents the ®rst example of a tumor where an Rb target (Id2) is recruited by a powerful oncogene (N-myc) to overcome the Rb tumor suppressor pathway (Figure 1 ).
Other studies have identi®ed Id proteins as critical downstream targets of proliferative and antiproliferative signaling pathways often perturbed in cancer. Mitogenic signals driven by estrogens, insulin growth factor-2 and T-cell receptor induce expression of Id1, Id2 and Id3, respectively (Bain et al., 2001; Belletti et al., 2001; Lin et al., 2000) . Recent data proposed that the extracellular signals that elevate the expression of Id might be mediated by the RasErk-Map kinase cascade and the PI3 kinase pathway (Bain et al., 2001; Belletti et al., 2001) . On the other hand, many antiproliferative signals are funneled through the down-regulation of Id gene expression. Prominent among the antimitogenic pathways that lead to decreased expression of Id proteins are those initiated by progesterone and TGFb (Chen et al., 2001; Lasorella et al., 2000; Lin et al., 2000) . Because constitutive activation of proliferative signals and disruption of antiproliferative circuits coexist in a variety of ways in dierent types of human tumors, it will not be surprising if alterations of Id proteins will be described in most, if not all human malignancies.
Future perspectives
At least four essential hallmark capabilities of malignancy are conferred by dysregulated expression of Id proteins during tumorigenesis: anaplasia, uncontrolled proliferation, sustained neoangiogenesis and invasion of neighboring tissues (Figure 2 ). The design of drugs targeting the abnormal Id signaling in cancer shows exceptionally promising potentialities. First, by hitting Id in tumor cells, these molecules might reconstitute the integrity of the Rb pathway, the most critical antiproliferative safeguard available to mammalian cells. They could also prevent invasiveness by limiting production of matrix metalloproteinases. Second, by hitting Id in the tumor vasculature, they could reduce oxygen and nutrients' supply to tumor cells. Neuroblastoma is the ®rst human tumor showing such a dual involvement of Id proteins. In this embryonal cancer, abnormal expression of Id2 in the tumor cells is associated with deregulated expression of Id1 and Id3 in the tumor blood vessels (Table 1 ). Resistance to conventional treatment and poor prognosis characterize almost invariably advanced neuroblastoma (clinical stage 4), (Katzenstein and Cohn, 1998) . We suggest that stage 4 neuroblastoma will be an excellent cancer model to test the ecacy of novel anti-Id drugs when these substances will become available. Among potential tumor targets for intervention, few other molecules oer the attractive targeting mechanisms against multiple essential traits of cancer that might be associated with the ablation of Id function in human malignancy. It will be the privilege of those dedicated to this exciting ®eld of research to attempt to render these promising hopes into reality.
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